.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, patients along with metastatic stomach tumors that obtained biomarker-matched therapies based on distributing tumor DNA profiling presented a better medical benefit than those acquiring unmatched treatment.